Medical device industry spends more on physician payments than pharma
A recent study finds that medical device companies spend more than pharma on payments to physicians, but spend it in different ways. More
The cardiac implant you get may depend on the company paying your doctor
Does receiving money from medical device companies impact the devices doctors implant in patients? A recent study in JAMA suggests that it does. More
Two ways to stop unnecessary stenting
Many cardiologists recognize that placing coronary stents for stable heart disease has limited clinical benefit for patients. But low-value stents are still common -- how can we change this practice? New research in JAMA Internal Medicine provides some suggestions. More
A silver lining to COVID-19: Fewer low-value elective procedures
A potential silver lining of the COVID-19 pandemic? An opportunity to permanently stop doing unnecessary elective procedures. More
FDA’s proposed reform for medical devices lacks teeth
In a recent Washington Post op-ed, Shannon Brownlee and Jeanne Lenzer explain why the FDA's proposed changes are unlikely to make a real difference in medical device safety. More
The real reason why ORBITA is groundbreaking
If you thought the only takeaway from ORBITA was "stents don't work," you're missing the point, says Dr. Vikas Saini in Health Affairs. More
The ORBITA debate continues: Authors refute letters in The Lancet
The ORBITA debate continues as the study authors respond to critical letters in The Lancet. More
The CABANA trial: Another cardiac procedure bites the dust?
Catheter ablation for atrial fibrillation has been used for 20 years, and grown into a $4.5 billion industry. But is the procedure actually effective? More
Can one study change clinical practice?
Professor Doug McKell explains why ORBITA might not be enough to reduce unnecessary stents. More
INTERVIEW: Dr. David Brown on startling stent study
Cardiologist David Brown addresses some of the criticisms of the controversial ORBITA trial. More